To evaluate the effect of hepatitis B vaccine in this combined formulation and to determine the rate of seroprotection in DRC, a country with a high prevalence of HBV.
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Hepatitis B virus (HBV) is a major health problem. [1, 2] Globally more than 2 billion people have been infected with HBV, and according to World Health Organization (WHO) estimates, 257 million people were living with chronic HBV infection in 2015. Among them, 60 million were from Africa. [2] [3] [4] After perinatal transmission, one of the major modes of transmission in Africa, up to 90% of infected infants develop chronic infection with the risk of cirrhosis, liver failure, cancer and premature death. [2, 5] Main routes of transmission are in utero, by exposure to blood or body fluids during birth, and horizontally during early life. Prevention of transmission of HBV from mother to child and during early life is therefore an important public health goal.
In 1992, the WHO recommended the integration of hepatitis B vaccination into the national immunisation programmes of highly endemic countries by 1995 and all other countries by 1997. [6] The vaccination schedule consists of three or four doses of hepatitis B vaccine and administration of HBV immunoglobulins to infants born to hepatitis B surface antigen (HBsAg)-positive mothers. In addition, the WHO recommended a first dose of hepatitis B vaccine within 24 hours of birth, especially in highly endemic countries (HBV prevalence >8%), with the objective of reducing the risk of early mother-to-child transmission. [7, 8] Hepatitis B vaccines are currently available not only in monovalent formulations but also in combinations that protect against HBV and several other diseases (e.g. diphtheria, tetanus and pertussis). Benefits of these combined vaccines include a reduction in the number of injections and the related cost, resulting in improved adherence to the vaccination programme. However, if immunisation against HBV begins at birth, only monovalent hepatitis B vaccine should be used, as the other antigens in combined vaccines are not approved for use at birth. For this reason, all combined vaccines are currently started 6 weeks after birth. [9] In 2007, the Democratic Republic of the Congo (DRC) adopted and implemented a universal infant hepatitis B immunisation programme consisting of administration of three doses of this vaccine in a combined formulation. Since 2009, it has been provided as an active pentavalent vaccine against diphtheria, tetanus, pertussis, Haemophilus influenzae type b and HBV (DTwP-Hib-HepB). The three doses of this vaccine are routinely administered to infants at the ages of 6, 10 and 14 weeks. Data recorded included pregnancy information, maternal and infant characteristics and laboratory results ( Table 1) . Some of these variables were chosen because they have been associated with variations in response rates following hepatitis B vaccine administration. [11] In our study, mothers and infants were consecutively enrolled during routine visits for the immunisation schedule.
[10] We included only infants who had received all three injections of hepatitis B vaccine according to their immunisation card. Infants who had not yet received the third dose were excluded. During the vaccination programme, anthropometric parameters of infants are monitored monthly up to 9 months.
Current immunisation schedule for children in DRC

Ethical considerations
The study design was approved by the Ethics Committee of the Catholic University of Bukavu, DRC (ref. no. UCB/CIE/ NC/03B/2014). Informed consent was obtained from all mothers before blood samples were collected.
Serological analyses
Samples from the mothers were analysed using reagents Determine HBV HBsAg (Inverness Medical Japan Ltd, Japan) for HBV and Determine HIV 1/2 (Abbott Diagnostics, USA) for HIV. The results were classified as positive or negative according to the manufacturers' instructions. Subjects who were positive for HBsAg and HIV were considered to be carriers of both viruses. Determination of immune response in the infants was performed with a quantitative test (MONOLISA anti-HBs EIA; Bio-Rad Laboratories, USA) in the first 122 samples and with a qualitative reagent (HBs antibodies ELISA test; Autobio Diagnostics, China) in the last 78 samples for economic reasons and because the former test was no longer available. The qualitative test consisted of an immunochromatographic assay in which results are interpreted by visual observation.
An inter-laboratory comparison was undertaken to guarantee the quality of laboratory results by exchanging 30 maternal samples with the laboratory at St Luc Hospital, Brussels, Belgium, in which serological tests were performed using the cobas 6000 analyser series (Roche, Switzerland).
Analysis of the immune response
For quantitative tests, a level of hepatitis B surface antibody (HBsAb) ≥10 mIU/mL was considered a good immunological response according to the WHO criteria. [4] According to the qualitative test's instructions, positive tests were considered as responders and negative tests as non-responders.
Statistical analysis
Results were expressed as means (standard deviations (SDs)). Bivariate analyses comparing two subgroups of infants, responders and non-responders, in terms of sociodemographic characteristics and associated clinical factors were performed using Student's t-test. Differences between qualitative data were evaluated using the χ 2 test. Statistical significance was set at p<0.05. Analyses were performed using Statistical Package for Social Sciences (SPSS) software version 17.0 (IBM, USA).
Results
A total of 200 consecutive infants who had received the three doses of hepatitis B vaccine were screened for immune response to vaccination. Their mothers' characteristics are set out in Table 2 . The mean (SD) age of the mothers was 29.3 (6) years and that of the infants 9.1 (2.4) months. Of the mothers, 97% had normal term pregnancies and 93% normal deliveries. No mother reported having been vaccinated against HBV, while the seroprevalences of HIV and HBsAg were 2% and 3%, respectively. The inter-laboratory comparison of these tests showed identical results between the two laboratories.
Of the infants, 19/122 in the group tested with the quantitative kit had an HBsAb level <10 mIU/mL and 12/78 were negative with the qualitative test, giving a total of 31 non-responders (15.5%) ( Table 3) . Table 3 also outlines the maternal and infant characteristics in the responders and non-responders. Factors such as maternal age, gestational age, parity and maternal HBsAg/HIV status were not found to significantly affect HBsAb levels in infants receiving the three doses of hepatitis B vaccine.
No statistically significant differences in sex or infant's weight at birth were observed between responders and non-responders.
Discussion
We present the immunological response observed after universal hepatitis B pentavalent vaccination performed at the age of 6, 10 and 14 weeks in the DRC. Our 15.5% rate of non-response seems high compared with rates of <10% in studies of infants of similar age. [12] [13] [14] [15] [16] Very few studies are available on the efficacy of hepatitis B vaccination in sub-Saharan Africa. In these studies, the first dose of vaccine was given after 4 weeks of age, and not at birth as recommended by the WHO. Nevertheless, our rate of seroprotection is lower than those found in previous studies in Gambia and South Africa (SA), which exceed 90%. [17, 18] It is, however, higher than the rate of 80% found in a similar study in Ivory Coast. [19] It should be noted that in the SA study the investigators suggested that the seroprotection rate of 93% could be due to a highly immunogenic 
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vaccine and a decline in HBeAg seroprevalence as a consequence of several years of vaccination. [17] In contrast to other reports, our study did not identify any maternal or intrinsic infant conditions associated with low immunological response. The mechanism of non-response to hepatitis B immunisation is still unknown, but factors associated with a low immune response rate are type of vaccine, age, male gender, obesity and smoking in healthy adults, and delayed administration, preterm birth, low birth weight and immunodeficiency in infants. [20, 21] In our patients, no statistically significant differences in these variables were observed between the responders and the nonresponders. Nevertheless, it must be noted that HBsAg and HBV DNA had not been tested before or at the time of hepatitis B vaccine administration. The possibility of an association between a certain type of HLA and impaired response has been suggested. [22, 23] Liu et al. [24] found that non-response to hepatitis B vaccination in healthy Chinese individuals was associated with HLA B54. In Taiwan, Hsu et al. [25] reported that absence of response or low response was associated with over-expression of HLA-DR14-DR52. The possibility that our low response rate was due to intrinsic factors such as individual characteristics of our study population or malnutrition, which has been reported to impair response to vaccine, [8] cannot be excluded. Several years of war in our investigation area (South Kivu Province) had had numerous socioeconomic consequences, including malnutrition in children.
Sub-Saharan countries represent a part of the world where hepatitis remains endemic and transmission frequently occurs in utero, during delivery or during the first years of life. Childhood immunisation therefore represents one of the goals of prevention of early-life transmission with its frequent chronic complications such as cirrhosis and hepatocellular carcinoma. [1, 3] Many studies have demonstrated a dramatic reduction in the incidences of HBV infection and associated complications as a result of the programme of childhood immunisation. [6, 20, 21, [26] [27] [28] [29] For example, in Southern Italy, previously considered an area of very high endemicity, the prevalence of HBsAg declined from 13.4% to 0.9% after 20 years of implementation of the vaccination programme. [20] Immunisation of all infants is therefore one of the WHO's recommendations in the fight against HBV worldwide. Although these recommendations are based on the slight potential advantage in reduction of early transmission following a birth dose of vaccine, implementation of a birth dose is not always feasible in low-income countries for logistical and economic reasons. [8, 18, 30, 31] In fact, only immunisation programmes with combined vaccines are currently sponsored by the WHO, and the monovalent vaccines (the only ones approved for use at birth) are not purchased by many African governments. [32] Only a few African countries have a hepatitis B vaccination programme with a birth dose (Nigeria, Gambia, Cape Verde), even if the first dose is not always given within 24 hours of birth as recommended, mainly for logistical and cultural reasons. [8] It must, however, be noted that no substantial difference in the response rate was reported in some studies comparing the immune response to hepatitis B vaccination given at birth or 4 or 6 weeks after delivery. [11, 19, 33, 34] 
Study limitations
Some limitations of this first study on HBV prevention in the DRC should be mentioned. These include the small size of our sample and the cross-sectional nature of the study. The latter in particular did not allow determination of middle/long-term protection. A prospective study could have identified the real rate of long-term protection, including slow responders. HBV DNA levels in the infants were not tested to identify occult HBV infection, and we did not determine maternal HBeAg/HBV DNA status. These factors should be taken into consideration when interpreting our findings. The relatively high rate of non-response in our study could in fact be related to some children having been infected prior to vaccination. [35] The switching from a quantitative to a qualitative anti-HBs test could also have affected our results, especially when interpreting borderline results with the qualitative test. 
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Conclusions
The study demonstrated that the rate of seroprotection after three doses of hepatitis B vaccine in Congolese infants is lower than desirable (>90%), but comparable to some data from other African countries with similar socioeconomic conditions. Further studies are needed to assess this finding and to evaluate ways to optimise the rate of seroprotection.
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